Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

Moderna held back on US vaccine policy changes as PDUFA dates near. (Shutterstock)

More from Vaccines

More from Pathways & Standards